![]() |
|||||
|
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() |
Gene: RPL29 |
Gene summary for RPL29 |
![]() |
Gene information | Species | Human | Gene symbol | RPL29 | Gene ID | 6159 |
Gene name | ribosomal protein L29 | |
Gene Alias | HIP | |
Cytomap | 3p21.2 | |
Gene Type | protein-coding | GO ID | GO:0000003 | UniProtAcc | P47914 |
Top |
Malignant transformation analysis |
![]() |
![]() |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
6159 | RPL29 | HTA11_99999965104_69814 | Human | Colorectum | MSS | 3.93e-44 | 2.31e+00 | 0.281 |
6159 | RPL29 | HTA11_99999971662_82457 | Human | Colorectum | MSS | 2.20e-118 | 3.77e+00 | 0.3859 |
6159 | RPL29 | HTA11_99999973899_84307 | Human | Colorectum | MSS | 3.60e-40 | 2.26e+00 | 0.2585 |
6159 | RPL29 | HTA11_99999974143_84620 | Human | Colorectum | MSS | 6.15e-112 | 2.95e+00 | 0.3005 |
6159 | RPL29 | A002-C-010 | Human | Colorectum | FAP | 3.11e-09 | 5.18e-01 | 0.242 |
6159 | RPL29 | A015-C-203 | Human | Colorectum | FAP | 1.76e-09 | 3.95e-01 | -0.1294 |
6159 | RPL29 | A002-C-201 | Human | Colorectum | FAP | 5.73e-12 | 6.43e-01 | 0.0324 |
6159 | RPL29 | A002-C-203 | Human | Colorectum | FAP | 5.53e-53 | 1.11e+00 | 0.2786 |
6159 | RPL29 | A015-C-006 | Human | Colorectum | FAP | 4.69e-03 | 3.69e-01 | -0.0994 |
6159 | RPL29 | A015-C-104 | Human | Colorectum | FAP | 5.45e-05 | 1.02e-01 | -0.1899 |
6159 | RPL29 | A001-C-014 | Human | Colorectum | FAP | 1.03e-06 | 4.24e-01 | 0.0135 |
6159 | RPL29 | A002-C-016 | Human | Colorectum | FAP | 1.13e-24 | 7.70e-01 | 0.0521 |
6159 | RPL29 | A015-C-002 | Human | Colorectum | FAP | 3.61e-03 | 4.48e-01 | -0.0763 |
6159 | RPL29 | A002-C-116 | Human | Colorectum | FAP | 8.45e-09 | 3.69e-01 | -0.0452 |
6159 | RPL29 | F072B | Human | Colorectum | FAP | 6.75e-04 | 3.92e-01 | 0.257 |
6159 | RPL29 | CRC-1-8810 | Human | Colorectum | CRC | 6.27e-45 | 1.06e+00 | 0.6257 |
6159 | RPL29 | CRC-3-11773 | Human | Colorectum | CRC | 1.68e-27 | 8.02e-01 | 0.2564 |
6159 | RPL29 | AEH-subject1 | Human | Endometrium | AEH | 1.06e-46 | -4.05e-01 | -0.3059 |
6159 | RPL29 | AEH-subject2 | Human | Endometrium | AEH | 1.76e-25 | -4.58e-01 | -0.2525 |
6159 | RPL29 | AEH-subject3 | Human | Endometrium | AEH | 1.22e-06 | -1.69e-01 | -0.2576 |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 |
![]() |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
![]() |
![]() |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | ![]() |
Colorectum | SER | ![]() |
Colorectum | MSS | ![]() |
Colorectum | MSI-H | ![]() |
Colorectum | FAP | ![]() |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:00021819 | Breast | Precancer | cytoplasmic translation | 80/1080 | 148/18723 | 1.59e-59 | 8.54e-56 | 80 |
GO:00075653 | Breast | Precancer | female pregnancy | 29/1080 | 193/18723 | 2.07e-06 | 7.31e-05 | 29 |
GO:00447063 | Breast | Precancer | multi-multicellular organism process | 31/1080 | 220/18723 | 3.73e-06 | 1.19e-04 | 31 |
GO:00075663 | Breast | Precancer | embryo implantation | 11/1080 | 53/18723 | 1.82e-04 | 2.95e-03 | 11 |
GO:000218114 | Breast | IDC | cytoplasmic translation | 82/1434 | 148/18723 | 2.60e-52 | 1.48e-48 | 82 |
GO:000756511 | Breast | IDC | female pregnancy | 39/1434 | 193/18723 | 1.81e-08 | 1.27e-06 | 39 |
GO:00447061 | Breast | IDC | multi-multicellular organism process | 41/1434 | 220/18723 | 8.58e-08 | 5.19e-06 | 41 |
GO:000756611 | Breast | IDC | embryo implantation | 14/1434 | 53/18723 | 3.14e-05 | 7.32e-04 | 14 |
GO:000218124 | Breast | DCIS | cytoplasmic translation | 82/1390 | 148/18723 | 2.21e-53 | 1.25e-49 | 82 |
GO:00075652 | Breast | DCIS | female pregnancy | 37/1390 | 193/18723 | 7.85e-08 | 4.47e-06 | 37 |
GO:00447062 | Breast | DCIS | multi-multicellular organism process | 39/1390 | 220/18723 | 3.05e-07 | 1.46e-05 | 39 |
GO:00075662 | Breast | DCIS | embryo implantation | 13/1390 | 53/18723 | 1.00e-04 | 1.82e-03 | 13 |
GO:000218110 | Cervix | CC | cytoplasmic translation | 96/2311 | 148/18723 | 4.87e-51 | 2.91e-47 | 96 |
GO:00075654 | Cervix | CC | female pregnancy | 43/2311 | 193/18723 | 7.62e-05 | 1.04e-03 | 43 |
GO:00447064 | Cervix | CC | multi-multicellular organism process | 45/2311 | 220/18723 | 4.14e-04 | 4.21e-03 | 45 |
GO:00075664 | Cervix | CC | embryo implantation | 15/2311 | 53/18723 | 1.43e-03 | 1.12e-02 | 15 |
GO:000218115 | Cervix | HSIL_HPV | cytoplasmic translation | 86/737 | 148/18723 | 3.97e-82 | 1.91e-78 | 86 |
GO:000756512 | Cervix | HSIL_HPV | female pregnancy | 26/737 | 193/18723 | 4.32e-08 | 3.41e-06 | 26 |
GO:004470611 | Cervix | HSIL_HPV | multi-multicellular organism process | 27/737 | 220/18723 | 1.69e-07 | 1.03e-05 | 27 |
GO:000756612 | Cervix | HSIL_HPV | embryo implantation | 10/737 | 53/18723 | 3.53e-05 | 9.72e-04 | 10 |
Page: 1 2 3 4 5 |
![]() |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
hsa0301018 | Breast | Precancer | Ribosome | 80/684 | 167/8465 | 7.33e-44 | 2.32e-41 | 1.77e-41 | 80 |
hsa0517118 | Breast | Precancer | Coronavirus disease - COVID-19 | 81/684 | 232/8465 | 3.74e-32 | 2.36e-30 | 1.81e-30 | 81 |
hsa0301019 | Breast | Precancer | Ribosome | 80/684 | 167/8465 | 7.33e-44 | 2.32e-41 | 1.77e-41 | 80 |
hsa0517119 | Breast | Precancer | Coronavirus disease - COVID-19 | 81/684 | 232/8465 | 3.74e-32 | 2.36e-30 | 1.81e-30 | 81 |
hsa0301024 | Breast | IDC | Ribosome | 83/867 | 167/8465 | 6.07e-39 | 9.87e-37 | 7.38e-37 | 83 |
hsa0517124 | Breast | IDC | Coronavirus disease - COVID-19 | 86/867 | 232/8465 | 1.50e-28 | 9.72e-27 | 7.27e-27 | 86 |
hsa0301034 | Breast | IDC | Ribosome | 83/867 | 167/8465 | 6.07e-39 | 9.87e-37 | 7.38e-37 | 83 |
hsa0517134 | Breast | IDC | Coronavirus disease - COVID-19 | 86/867 | 232/8465 | 1.50e-28 | 9.72e-27 | 7.27e-27 | 86 |
hsa0301044 | Breast | DCIS | Ribosome | 82/846 | 167/8465 | 8.69e-39 | 1.40e-36 | 1.03e-36 | 82 |
hsa0517144 | Breast | DCIS | Coronavirus disease - COVID-19 | 86/846 | 232/8465 | 2.42e-29 | 1.56e-27 | 1.15e-27 | 86 |
hsa0301054 | Breast | DCIS | Ribosome | 82/846 | 167/8465 | 8.69e-39 | 1.40e-36 | 1.03e-36 | 82 |
hsa0517154 | Breast | DCIS | Coronavirus disease - COVID-19 | 86/846 | 232/8465 | 2.42e-29 | 1.56e-27 | 1.15e-27 | 86 |
hsa0517120 | Cervix | CC | Coronavirus disease - COVID-19 | 111/1267 | 232/8465 | 1.82e-33 | 5.90e-31 | 3.49e-31 | 111 |
hsa0301020 | Cervix | CC | Ribosome | 85/1267 | 167/8465 | 3.17e-28 | 5.14e-26 | 3.04e-26 | 85 |
hsa05171110 | Cervix | CC | Coronavirus disease - COVID-19 | 111/1267 | 232/8465 | 1.82e-33 | 5.90e-31 | 3.49e-31 | 111 |
hsa03010110 | Cervix | CC | Ribosome | 85/1267 | 167/8465 | 3.17e-28 | 5.14e-26 | 3.04e-26 | 85 |
hsa0301025 | Cervix | HSIL_HPV | Ribosome | 80/459 | 167/8465 | 9.61e-58 | 2.82e-55 | 2.28e-55 | 80 |
hsa0517125 | Cervix | HSIL_HPV | Coronavirus disease - COVID-19 | 91/459 | 232/8465 | 2.14e-56 | 3.13e-54 | 2.53e-54 | 91 |
hsa0301035 | Cervix | HSIL_HPV | Ribosome | 80/459 | 167/8465 | 9.61e-58 | 2.82e-55 | 2.28e-55 | 80 |
hsa0517135 | Cervix | HSIL_HPV | Coronavirus disease - COVID-19 | 91/459 | 232/8465 | 2.14e-56 | 3.13e-54 | 2.53e-54 | 91 |
Page: 1 2 3 4 5 6 7 |
Top |
Cell-cell communication analysis |
![]() |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
![]() |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
![]() |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
RPL29 | SNV | Missense_Mutation | rs764458055 | c.208N>A | p.Glu70Lys | p.E70K | P47914 | protein_coding | tolerated(0.08) | benign(0.01) | TCGA-A5-A0G2-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
RPL29 | SNV | Missense_Mutation | rs375605221 | c.271C>T | p.Arg91Cys | p.R91C | P47914 | protein_coding | tolerated(0.47) | benign(0) | TCGA-AJ-A3BG-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Chemotherapy | carboplatin | PD |
RPL29 | SNV | Missense_Mutation | c.205N>A | p.Ala69Thr | p.A69T | P47914 | protein_coding | tolerated(0.07) | benign(0.062) | TCGA-AP-A059-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
RPL29 | SNV | Missense_Mutation | c.53G>A | p.Arg18Lys | p.R18K | P47914 | protein_coding | deleterious(0.04) | probably_damaging(0.944) | TCGA-B5-A0JY-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | doxorubicin | SD | |
RPL29 | SNV | Missense_Mutation | novel | c.382N>G | p.Lys128Glu | p.K128E | P47914 | protein_coding | tolerated(0.15) | benign(0) | TCGA-EO-A22X-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Unspecific | Carboplatin | Complete Response |
RPL29 | SNV | Missense_Mutation | novel | c.165N>T | p.Lys55Asn | p.K55N | P47914 | protein_coding | deleterious(0.01) | probably_damaging(0.981) | TCGA-EO-A3B0-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
RPL29 | SNV | Missense_Mutation | novel | c.139N>G | p.Lys47Glu | p.K47E | P47914 | protein_coding | deleterious(0.04) | benign(0.221) | TCGA-UB-A7MB-01 | Liver | liver hepatocellular carcinoma | Male | <65 | I/II | Targeted Molecular therapy | sorafenib | PD |
RPL29 | SNV | Missense_Mutation | novel | c.130N>T | p.Arg44Cys | p.R44C | P47914 | protein_coding | tolerated(0.27) | benign(0) | TCGA-XK-AAIW-01 | Prostate | prostate adenocarcinoma | Male | >=65 | 9 | Unknown | Unknown | PD |
RPL29 | SNV | Missense_Mutation | rs772176036 | c.320G>A | p.Arg107His | p.R107H | P47914 | protein_coding | tolerated(0.41) | benign(0) | TCGA-F1-A448-01 | Stomach | stomach adenocarcinoma | Male | >=65 | III/IV | Chemotherapy | capecitabine | CR |
Page: 1 |
Top |
Related drugs of malignant transformation related genes |
![]() |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |